| Title |
A retrospective observational study to
assess imaging and management of
patients with castration-resistant
prostate cancer |
| Protocole ID |
AMGEN 20150126 |
| ClinicalTrials.gov ID |
|
| Cancer Type(s) |
Prostate |
| Phase |
Other |
| Stage |
|
| Study Type |
|
| Drug |
|
| Institution |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
1001 boul. Décarie , Montréal, QC, H4A 3J1
|
| City |
Montréal |
| Principal Investigator |
Dr. Armen Aprikian
|
| Coordinator |
Maria Simona Grigorie
514-934-1934 poste 35160
|
| Status |
Recruiting |
| Activation Date |
27-05-2016 |
| Eligibility Criteria |
-
Men diagnosed with castration-resistant prostate cancer, defined as a recorded PSA
-
value of ≥2 ng/mL despite ongoing androgen deprivation therapy (ADT)
-
Patient has completed at least one follow-up clinic visit subsequent to the development of castration-resistance (the date of this clinic visit defines the index date)
-
Age ≥18 years at index date
-
Patient can have prior or current evidence of detectable bone or visceral metastasis(es) and MUST have completed at least one additional follow-up visit subsequent to the identification of bone/visceral metastases and the patient’s chart contains details of this follow-up visit
|
| Exclusion Criteria |
-
Patient had evidence of detectable bone or visceral metastasis(es) at index date
-
Patient has received investigational agent(s) or completed investigational procedures as part of a non-metastatic CRPC clinical study protocol
|
| |
|
Groupe d'étude en oncologie du Québec